In this study, we observed lysosomal changes as a prominent phenotype induced by CDK4/6i in different breast cancer cell types and evaluated the potential therapeutic effect of exposing CDK4/6i-treated breast cancer cells to lysosomotropic agents. This evidence concerns the gene CDK4 and breast cancer.